AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 3 - (NewsRx.com & NewsRx.net) -- The number of doses of meningococcal C-tetanus toxoid conjugate vaccine can be reduced without loss of immunogenicity in infants.
According to a study from England, "It has been previously shown that one of the three meningococcal C conjugate (MCC) vaccines introduced in the United Kingdom proved highly immunogenic after the first dose of a three-dose schedule, with evidence of immune memory after dose 3. Thus, in infants a one- or two-dose schedule of this MCC vaccine, conjugated to tetanus toxoid (TT), may suffice."
"Healthy infants (n=586) were randomized to receive either one (group 1), two (group 2), or three (group 3) doses of MCC-TT vaccine with a 10-microgram polysaccharide booster given at 13 to 14 months of age," reported Ray Borrow and collaborators at the Public Health Laboratory Service in London and Manchester. "Serum bactericidal antibody (SBA) levels were measured by utilizing rabbit complement (rSBA), meningococcal C-specific immunoglobulin G (IgG), and avidity indices (AIs)."
Borrow and his collaborators reported, "For groups 1, 2, and 3, the percentages of infants with an rSBA level of greater than or equal to8 against strain C11 were 98.4, 100, and 99.4%, respectively. Infants in group I with prevaccination rSBA titers of greater than or equal to8 had post-primary MCC rSBA geometric mean titers (GMTs) ...